Advanced search
Publication Cover
Platelets Volume 27, 2016 - Issue 5
Submit an article Journal homepage
387
Views
22
CrossRef citations to date
0
Altmetric
Original Article

Comparison of half- and standard-dose ticagrelor in Chinese patients with NSTE-ACS

H. J. XueCardiovascular Department, The First Clinical Hospital, Harbin Medical University, Harbin, P. R. China
,
J. ShiCardiovascular Department, The First Clinical Hospital, Harbin Medical University, Harbin, P. R. China
,
B. LiuCardiovascular Department, The First Clinical Hospital, Harbin Medical University, Harbin, P. R. China
,
D. Y. WangCardiovascular Department, The First Clinical Hospital, Harbin Medical University, Harbin, P. R. China
,
Z. X. DongCardiovascular Department, The First Clinical Hospital, Harbin Medical University, Harbin, P. R. China
,
H. GuoCardiovascular Department, The First Clinical Hospital, Harbin Medical University, Harbin, P. R. China
,
Y. H. KongCardiovascular Department, The First Clinical Hospital, Harbin Medical University, Harbin, P. R. China
,
L. ShengCardiovascular Department, The First Clinical Hospital, Harbin Medical University, Harbin, P. R. China
,
Q. ShaoCardiovascular Department, The First Clinical Hospital, Harbin Medical University, Harbin, P. R. China
,
D. H. SunCardiovascular Department, The First Clinical Hospital, Harbin Medical University, Harbin, P. R. China
,
L. ZhangCardiovascular Department, The First Clinical Hospital, Harbin Medical University, Harbin, P. R. China
,
Y. J. PanCardiovascular Department, The First Clinical Hospital, Harbin Medical University, Harbin, P. R. China
,
X. W. DongCardiovascular Department, The First Clinical Hospital, Harbin Medical University, Harbin, P. R. China
,
J. Q. LiCardiovascular Department, The First Clinical Hospital, Harbin Medical University, Harbin, P. R. China
,
J. Y. XueCardiovascular Department, The First Clinical Hospital, Harbin Medical University, Harbin, P. R. China
,
Y. Y. ZhouCardiovascular Department, The First Clinical Hospital, Harbin Medical University, Harbin, P. R. China
,
H. P. YangCardiovascular Department, The First Clinical Hospital, Harbin Medical University, Harbin, P. R. China
&
Y. LiCardiovascular Department, The First Clinical Hospital, Harbin Medical University, Harbin, P. R. ChinaCorrespondence[email protected]
 show all
Pages 440-445 | Received 05 Aug 2015, Accepted 14 Dec 2015, Published online: 02 Feb 2016

References

  • Dhillon S. Ticagrelor: A review of its use in adults with acute coronary syndromes. Am J Cardiovasc Drugs 2015;15(1):51–68.
  • Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ; ACC/AHA Task Force Members. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;130(25):2354–2394.
  • Authors/Task Force Members, Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2016;37(3):267–315.
  • Tanguay JF, Bell AD, Ackman ML, Bauer RD, Cartier R, Chan WS, Douketis J, Roussin A, Schnell G, Verma S, Wong G, Mehta SR; Canadian CardiovascularSociety. Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. Can J Cardiol 2013;29(11):1334–1345.
  • James SK, Roe MT, Cannon CP, Cornel JH, Horrow J, Husted S, Katus H, Morais J, Steg PG, Storey RF, Stevens S, Wallentin L, Harrington RA; PLATO Study Group. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: Substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ 2011;342:d3527.
  • Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–1057
  • Cannon C, Harrington R, James S, Ardissino D, Becker R, Emanuelsson H, Husted S, Katus H, Keltaih M, Khurmi N, Kontny F, Lewis B, Steg P, Storey R, Wojdyla D, Wallentin L, the PLATelet inhibition and patient Outcomes (PLATO) investigators. Ticagrelor compared with clopidogrel in acute coronary syndromes patients with a planned invasive strategy (PLATO): A randomized double-blind study. Lancet 2010;375:283–293.
  • Levine GN, Jeong YH, Goto S, Anderson JL, Huo Y, Mega JL, Taubert K, Smith SC Jr. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol 2014;11(10):597–606.
  • Guo LZ, Kim MH, Jin CD, Lee JY, Yi SJ, Park MK, Cho YR, Park TH. Comparison of pharmacodynamics between low dose ticagrelor and clopidogrel after loading and maintenance doses in healthy Korean subjects. Platelets 2015;26;563–569.
  • Hiasa Y, Teng R, Emanuelsson H. Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease. Cardiovasc Interv Ther 2014;29(4):324–333.
  • Li H, Butler K, Yang L, Yang Z, Teng R. Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: An open-label, sequential, two-cohort, single-centre study. Clin Drug Invest 2012;32(2):87–97.
  • Aradi D, Storey RF, Komo´csi A, Trenk D, Gulba D, Kiss RG, Husted S, Bonello L, Sibbing D, Collet JP, Huber K; Working Group on Thrombosis of the European Society of Cardiology. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J 2014;35:209–215.
  • Jeong YH, Bliden KP, Antonino MJ, Park KS, Tantry US, Gurbel PA. Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies. Am Heart J 2012;164(1):35–42.
  • Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK, Cornel JH, French J, Held C, Horrow J, Husted S, Lopez-Sendon J, Lassila R, Mahaffey KW, Storey RF, Harrington RA, Wallentin L. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2011;32(23):2933–2944.
  • Jeong KH, Cho JH, Woo JS, Kim JB, Kim WS, Lee TW, Kim KS, Ihm CG, Kim W. Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: A randomized crossover study. Am J Kidney Dis 2015 Jun;65(6):916–924.
  • Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Ophuis TO, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372(19):1791–1800.
  • Kang HJ, Clare RM, Gao R, Held C, Himmelmann A, James SK, Lim ST, Santoso A, Yu CM, Wallentin L, Becker RC; PLATO Investigators. Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Am Heart J 2015;169(6):899–905.e1.
  • Varenhorst C, Eriksson N, Johansson Å, Barratt BJ, Hagström E, Åkerblom A, Syvänen AC, Becker RC, James SK, Katus HA, Husted S, Steg PG, Siegbahn A, Voora D, Teng R, Storey RF, Wallentin L; PLATO Investigators. Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. Eur Heart J 2015;36(29):1901–1912.
  • Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 2013;94(3):317–323.
  • Schuette C, Steffens D, Witkowski M, Stellbaum C, Bobbert P, Schultheiss HP, Rauch U. The effect of clopidogrel on platelet activity in patients with and without type-2 diabetes mellitus: A comparative study. Cardiovasc Diabetol 2015;14:15.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.